Akebia Therapeutics (AKBA) Total Current Liabilities (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Total Current Liabilities of $173.9 million for Q1 2026, up 90.61% year-over-year from $91.2 million in Q1 2025, and up 6.72% quarter-over-quarter from $162.9 million in Q4 2025.
Akebia Therapeutics (AKBA) Total Current Liabilities (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Total Current Liabilities for 14 consecutive years, with $173.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 90.61% year-over-year to $173.9 million; the TTM figure through Mar 2026 stood at $173.9 million (up 90.61% YoY), while the FY2025 annual figure was $162.9 million, up 101.37% from the prior year.
- Total Current Liabilities rose to $173.9 million in Q1 2026 per AKBA's latest filing, from $162.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $258.5 million in Q1 2022 and bottomed at $65.7 million in Q3 2024.
- Historically, Total Current Liabilities has averaged $128.1 million across 5 years, with a median of $107.3 million in 2024.
- Annual changes were most pronounced in 2023 — Total Current Liabilities sank 66.09% — and 2025, when it soared 102.98%.
- Akebia Therapeutics' Total Current Liabilities stood at $129.5 million in 2022, then dropped by 22.9% to $99.9 million in 2023, then dropped by 18.98% to $80.9 million in 2024, then surged by 101.37% to $162.9 million in 2025, then grew by 6.72% to $173.9 million in 2026.
- Business Quant data shows AKBA's Total Current Liabilities at $173.9 million in Q1 2026, $162.9 million in Q4 2025, and $133.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 160.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 160.87 Mn |
| Mar 31, 2026 | 173.88 Mn |
| Dec 31, 2025 | 162.94 Mn |
| Sep 30, 2025 | 133.38 Mn |
| Jun 30, 2025 | 118.72 Mn |
| Mar 31, 2025 | 91.23 Mn |
| Dec 31, 2024 | 80.91 Mn |
| Sep 30, 2024 | 65.71 Mn |
| Jun 30, 2024 | 107.30 Mn |
| Mar 31, 2024 | 66.49 Mn |
| Dec 31, 2023 | 99.87 Mn |
| Sep 30, 2023 | 79.70 Mn |
| Jun 30, 2023 | 92.18 Mn |
| Mar 31, 2023 | 87.66 Mn |
| Dec 31, 2022 | 129.54 Mn |
| Sep 30, 2022 | 193.13 Mn |
| Jun 30, 2022 | 237.40 Mn |
| Mar 31, 2022 | 258.50 Mn |
| Dec 31, 2021 | 261.05 Mn |
| Sep 30, 2021 | 189.21 Mn |